The European Medicines Agency is considering advising doctors to more closely monitor patients treated with Novartis’ gene therapy Zolgensma for liver injury, according to a notice put out Friday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,